Eli Lilly and Company: Atherosclerosis trials
The registry lists 10 Atherosclerosis studies with Eli Lilly and Company as lead sponsor. 5 are open to participants now and 2 have results posted.
Phase 1 1Phase 2 4Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseRecruitingNCT07839936Phase 2
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventRecruitingNCT07783802Phase 2
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High RiskRecruitingNCT07613294Phase 3
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)RecruitingNCT07157774Phase 3
- Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular DiseaseEnrolling by invitationNCT06112327
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsCompletedNCT05563246Phase 2Results posted
- A Study of LY2484595 in Patients With High LDL-C or Low HDL-CCompletedNCT01105975Phase 2Results posted
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingNCT06383390Phase 3
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)Active, not recruitingNCT06292013Phase 3
- A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular DiseaseCompletedNCT05398029Phase 1